'JUN - 5 2009



BD ProbeTecTM Neisseria gonorrhoeae (GC) Q^x Amplified DNA Assay

BD Diagnostic Systems Applicant 7 Loveton Circle Sparks, MD 21152 **Establishment Registration No.** 1119779 **Contact Person** Kathryn Babka Carr, RAC tel. 410-316-4260 fax. 410-316-4041 Kathy Carr@bd.com **Summary Date** April 3, 2009 BD ProbeTec[™] Neisseria gonorrhoeae (GC) Q^x Amplified **Proprietary Name** DNA Assay DNA probe, nucleic acid amplification, Neisseria Generic Name Class II Classification **Classification Name** Neisseria spp. direct serological test reagents **Regulation Number** 866.3390 LSL **Product Code** BD ProbeTecTM Neisseria gonorrhoeae (GC) O^x Amplified **Predicate Devices** DNA Assav (K081825) Gen-Probe Amplified Neisseria gonorrhoeae Assay (K043144) **Device Description**

The **BD** ProbeTec GC Q^x Amplified DNA Assay is based on the simultaneous amplification and detection of target DNA using amplification primers and a fluorescently-labeled detector probe. The reagents for SDA are dried in two separate disposable microwells: the Priming Microwell contains the amplification primers, fluorescently-labeled detector probe, nucleotides and other reagents necessary for amplification, while the Amplification Microwell contains the two enzymes (a DNA polymerase and a restriction endonuclease) that are required for SDA. The **BD** ViperTM System pipettes a portion of the purified DNA solution from each Extraction Tube into a Priming Microwell to rehydrate the contents. After a brief incubation, the reaction mixture is transferred to a corresponding, pre-warmed Amplification Microwell which is sealed to prevent contamination and then incubated in one of the two thermally-controlled fluorescent readers. The presence of *N. gonorrhoeae* DNA is determined by calculating the peak fluorescence (Maximum Relative Fluorescent Units (MaxRFU)) over the course of the amplification process and by comparing this measurement to a predetermined threshold value.



BD ProbeTec[™] Neisseria gonorrhoeae (GC) Q^x Amplified DNA Assay

In addition to the fluorescent probe used to detect amplified *N. gonorrhoeae* target DNA, a second labeled oligonucleotide is incorporated in each reaction. The Extraction Control (EC) oligonucleotide is labeled with a different dye than that used for detection of the *N. gonorrhoeae* -specific target and is used to confirm the validity of the extraction process. The EC is dried in the Extraction Tubes and is rehydrated upon addition of the specimen and extraction reagents. At the end of the extraction process, the EC fluorescence is monitored by the **BD Viper System** and an automated algorithm is applied to both the EC and *N. gonorrhoeae* -specific signals to report results as positive, negative, or EC failure.

Intended Use

The **BD ProbeTecTM** *Neisseria gonorrhoeae* (GC) Q^x Amplified DNA Assay, when tested with the BD ViperTM System in extracted mode, uses Strand Displacement Amplification (SDA) technology for the direct, qualitative detection of *Neisseria gonorrhoeae* DNA in clinician-collected female endocervical and male urethral swabs, patient-collected vaginal swab specimens (in a clinical setting), and female and male urine specimens. The assay is indicated for use with asymptomatic and symptomatic female and male individuals to aid in the diagnosis of gonococcal urogenital disease.

Clinical Performance Characteristics

Clinician-collected endocervical and male urethral swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female Q^x UPT and neat urine specimens were collected from 1059 symptomatic and asymptomatic female subjects and 787 symptomatic and asymptomatic male subjects attending OB/GYN, sexually transmitted disease (STD) and family planning clinics at seven geographically diverse clinical sites in North America. Subjects were classified as symptomatic if they reported symptoms such as dysuria, urethral discharge, coital pain/difficulty/bleeding, testicular or scrotum pain/swelling, abnormal vaginal discharge, or pelvic/uterine/adnexal pain. Subjects were classified as asymptomatic if they did not report symptoms. Sixty five female subjects and 13 male subjects were excluded from the data analysis due to age requirement violations, antibiotic treatment in the last 21 days, opting to withdraw from the study after initially consenting, failure to obtain paired swab and urine specimens, urine quantity less than 20 mL, or transport and storage errors related to specimen collection. Therefore, the final data analysis included 994 compliant female subjects and 774 compliant male subjects.

Five specimens were collected from each of the 994 eligible female subjects. A urine specimen was collected and split into Q^x UPT, neat urine and the two reference urine specimen collection devices followed by a vaginal swab specimen and three randomized endocervical swab specimens. Up to four specimens were collected from each of the 774 eligible male subjects. Up to three randomized urethral swab specimens were collected followed by a urine specimen that was split into Q^x UPT, neat urine and the two reference urine specimen collection devices.



ł

BD ProbeTec[™] Neisseria gonorrhoeae (GC) Q^x Amplified DNA Assay

BD ProbeTec GC Q^x assay results were generated from the Q^x UPT and neat urine specimens, the vaginal swab specimen, one endocervical swab specimen and one male urethral swab specimen. The remaining two endocervical swab specimens, up to two male urethral swab specimens, and the two reference urine specimens for each male and female subject were tested using two reference methods: the BD ProbeTec ET GC/AC assay and another commercially available NAAT (Nucleic Acid Amplification Test). Specimen testing was conducted either at the site of collection or at a designated BD Viper testing site.

All performance calculations were based on the total number of **BD ProbeTec** GC Q^x assays results for endocervical, vaginal and male urethral swab specimens, and male and female Q^x UPT and neat urine specimens compared to a patient infected status (PIS) algorithm for each gender. In the algorithm, the designation of a subject as being infected with GC or not was based on endocervical swab and urine specimen results from the commercially available **BD ProbeTec** ET GC/AC assay and the other commercially available NAAT. Subjects were considered infected with GC if two of the four endocervical swab and urine specimens (or two of the three or four urethral swab and urine specimens) tested positive in the **BD ProbeTec** ET GC/AC assay and the other reference NAAT (one specimen testing positive in each NAAT). Subjects were considered if less than two reference NAAT results were positive. A total of 6284 **BD ProbeTec** GC Q^x assay results from symptomatic and asymptomatic female and male were used to calculate sensitivity and specificity. Sensitivity and specificity by specimen type and symptomatic status are presented in **Table 3**.



BD ProbeTecTM Neisseria gonorrhoeae (GC) Q^x Amplified DNA Assay

Table 3: GC Q^x Assay Performance Compared to Patient Infected Status (by specimen type and symptomatic status)

			Performance Compared to Patient Infected Status						-
Specimen Type	Symptomatic	N	Sensitivity	95% C.I.	Specificity	95% C.I.	PPV	NPV	Error Initial/Final
FS	А	450	96.3% (26/27)	(81.0% - 99.9%)	99.5% (421/423)	(98.3% - 99.9%)	92.5%	99.8%	3/0
	S .	542	100.0% (38/38)	(90.7% - 100.0%)	99.8% (503/504)	(98.9% - 100.0%)	97.4%	100.0%	2/2
	Total	992	98.5% (64/65)	(91.7% - 100.0%)	99.7% (924/927)	(99.1% - 99.9%)	95.9%	99.9%	5/2
FV	A	449	100.0% (27/27)	(87.2% - 100.0%)	98.6% (416/422)	(96.9% - 99.5%)	82.0%	100.0%	0/0
	S	544	100.0% (38/38)	(90.7% - 100.0%)	99.6% (504/506)	(98.6% - 100.0%)	95.0%	100.0%	0/0
	Total	993	100.0% (65/65)	(94.5% - 100.0%)	99.1% (920/928)	(98.3% - 99.6%)	88.5%	100.0%	0/0
FNU	A	450	96.3% (26/27)	(81.0% - 99.9%)	99.3% (420/423)	(97.9% - 99.9%)	89.8%	99.8%	0/0
	S	543	97:4% (37/38)	(86.2% - 99.9%)	99.6% (503/505)	(98.6% - 100.0%)	94.8%	99.8%	0/0
	Total	993	96.9% (63/65)	(89.3% - 99.6%)	99.5% (923/928)	(98.7% - 99.8%)	93.1%	99.8%	0/0
FUPT	A	450	100.0% (27/27)	(87.2% - 100.0%)	99.5% (421/423)	(98.3% - 99.9%)	92.7%	100.0%	0/0
	S	543	97.4% (37/38)	(86.2% - 99.9%)	99.8% (504/505)	(98.9% - 100.0%)	97.3%	99.8%	0/0
	Total	993	98.5% (64/65)	(91.7% - 100.0%)	99.7% (925/928)	(99.1% - 99.9%)	95.8%	99.9%	0/0
MS ¹	A	508	100.0% (12/12)	(73.5% - 100.0%)	99.2% (492/496)	(97.9% - 99.8%)	75.5%	100.0%	0/0
	S	257	100.0% (100/100)	(96.4% - 100.0%)	98.7% (155/157)	(95.5% - 99.8%)	98.0%	100.0%	1/0
	Total ·	765	100.0% (112/112)	(96.8% - 100.0%)	99.1% (647/653)	(98.0% - 99.7%)	95.0%	100.0%	1/0

¹ Clinical Trial enrollment for asymptomatic male subjects was extended to obtain the total number of clinical positives for this sub-population.



r

510(k) Summary

BD ProbeTecTM Neisseria gonorrhoeae (GC) Q^x Amplified DNA Assay

	Symptomatic		Performance Compared to Patient Infected Status						
Specimen Type		N	Sensitivity	95% C.I.	Specificity	95% C.I.	PPV	NPV	Error Initial/Final
MNU ¹	А	517	100.0% (12/12)	(73.5% - 100.0%)	99.2% (501/505)	(98.0% - 99.8%)	74.6%	100.0%	0/0
	S	257	100.0% (100/100)	(96.4% - 100.0%)	98.1% (154/157)	(94.5% - 99.6%)	97.1%	100.0%	0/0
	Total	774	100.0% (112/112)	(96.8% - 100.0%)	98.9% (655/662)	(97.8% - 99.6%)	93.9%	100.0%	0/0
MUPT	A	517	100.0% (12/12)	(73.5% - 100.0%)	99.2% (501/505)	(98.0% - 99.8%)	74.6%	100.0%	1/0
	S	257	100.0% (100/100)	(96.4% - 100.0%)	98.7% (155/157)	(95.5% - 99.8%)	98.0%	100.0%	0/0
	Total	774	100.0% (112/112)	(96:8% - 100.0%)	99.1% (656/662)	(98.0% - 99.7%)	95.0%	100.0%	1/0
Total		6284	99.3% (592/596)	(98.3% - 99.8%)	99.3% (5650/5688)	(99.1% - 99.5%)	93.7%	99.9%	7/2

 A
 Asymptomatic

 CI
 Confidence Interval

 FNU
 Female Neat Urine

 FS
 Female endocervical swab

 FUPT
 Female urine in Q[×] UPT

 FV
 Female vaginal swab

 MNU
 Male Neat Urine

 MS
 Male urethral swab

 MUPT
 Male urethral swab


 MUPT
 Male urethral swab


 S
 Symptomatic



BD ProbeTecTM Neisseria gonorrhoeae (GC) Q^x Amplified DNA Assay

A total of 6284 GC Q^x Assay results was evaluated at seven geographically diverse clinical sites. A frequency distribution of the initial MaxRFU values for the GC Q^x assay with an assay cutoff of 125 MaxRFU is shown in **Figure A**.





Conclusions

The clinical study results for the **BD ProbeTec** *Neisseria gonorrhoeae* (GC) Q^x Amplified DNA Assay support the determination of substantial equivalence in accordance with the intended use as stated in the product labeling for the addition of asymptomatic males specimens.

DEPARTMENT OF HEALTH & HUMAN SERVICES



Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

JUN - 5 2009

Ms. Kathryn Babka Carr Regulatory Affairs Specialist BD Diagnostics Systems Becton, Dickinson and Company 7 Loveton Circle Sparks, MD 21152

Re: K090971

Trade/Device Name: BD ProbetecTM Nesseria gonorrhoeae (GC) Q^X Amplified DNA Assay

Regulation Number: 21 CFR 866.3390 Regulation Name: *Nesseria* spp. Direct serological test reagents Regulatory Class: Class II Product Code: LSL Dated: April 3, 2009 Received: April 6, 2009

Dear Ms. Carr:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Sall attom

Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of *In Vitro* Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known):

Device Name: BD ProbeTec[™] Neisseria gonorrhoeae (GC) Q^x Amplified DNA Assay

Indications For Use:

The **BD** ProbeTecTM Neisseria gonorrhoeae (GC) Q^x Amplified DNA Assay, when tested with the **BD** ViperTM System in extracted mode, uses Strand Displacement Amplification (SDA) technology for the direct, qualitative detection of Neisseria gonorrhoeae DNA in cliniciancollected female endocervical and male urethral swabs, patient-collected vaginal swab specimens (in a clinical setting), and female and male urine specimens. The assay is indicated for use with asymptomatic and symptomatic female and male individuals to aid in the diagnosis of gonococcal urogenital disease.

The BD Viper System, when used with the BD ProbeTec amplified nucleic assay(s), is intended for the *in vitro* detection of targeted organisms from specimens as identified in the assay-specific reagent package insert(s).

Prescription Use $\sqrt{}$ (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use _____ (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

Page 1 of 1

51000 kog 0971

BD Diagnostic Systems Becton, Dickinson and Company

Page vi